Document:

EX-10.20

 Exhibit 10.20 
 March 1, 2004 
 Harold Van Wart 
 80 Arbuelo Way 
 Los Altos, CA 94022 
 Dear Hal: 
 Metabolex, Inc. (the “Company”) is pleased to continue your employment as
President and Chief Executive Officer (“CEO”) on the following terms: 
 1. Position, Duties and Responsibilities.
As President and CEO, you will continue to report to the Company’s Board of Directors (the “Board”), and will perform the duties customarily associated with this position and such other duties assigned by the Board. You shall
devote your full time and attention during normal business hours to the business affairs of the Company, except for reasonable vacations and periods of illness or incapacity. 
 2. Compensation and Employee Benefits. 
 2.1 Base Salary. Your
annual base salary will continue to be $325,357, less payroll deductions and required withholdings, paid according to the Company’s regular payroll schedule and procedures. 

2.2 Discretionary Bonus. You will be eligible to earn an annual discretionary bonus of up to thirty-five percent (35%) of
your annual base salary based on the Company’s performance and your contributions in a given calendar year, as evaluated by the Board in its sole discretion. You will be eligible for any such bonus if you are employed at the end of the bonus
period (December 31). Any bonus payment shall be subject to payroll deductions and required withholdings. 
 2.3 Signing
Bonus. Notwithstanding your offer letter dated September 8, 2000, the one-time signing bonus of $145,000 that you received upon joining the Company will no longer be subject to repayment if you leave the Company prior to October 14,
2004. 
 2.4 Employee Benefits. You shall continue to be entitled to all benefits, including vacation accrual of four
weeks per year and health and disability benefits, for which you are eligible under the terms and conditions of the standard Company benefit plans, which may be in effect from time to time and provided by the Company to its senior executive level
employees generally. 
 2.5 Stock Options. On January 12, 2004, you were granted a stock option to purchase that
number of shares of Company common stock which together with the shares of Company common stock held by you or subject to your currently outstanding stock options constitute four and one quarter percent (4.25%) of the “fully-diluted”
outstanding capital stock of 

 
the Company calculated as of the date of grant (including as outstanding any outstanding but unexercised options and warrants to purchase Company capital stock and the conversion of all preferred
stock into common stock at the then-applicable conversion rate, but excluding any remaining unallocated shares available for issuance under the Company’s equity incentive plans). The per share exercise price of such stock options was equal to
the per share fair market value of the common stock on the date of grant, as determined by the Board. The term of such stock option is ten (10) years, subject to earlier expiration in the event of the termination of your service with the
Company. Such stock option is immediately exercisable, if you elect to do so, but the purchased shares shall be subject to repurchase by the Company at the lower of (1) the original exercise price and (2) the then-fair market value of the
Company’s common stock in the event that your service with the Company terminates before you become vested in the shares. You have vested, and the Company’s repurchase right, if applicable, shall not apply, as to twenty-five percent
(25%) of the shares immediately upon the date of grant, and as to the balance of the option shares in forty-eight (48) equal monthly installments with the first monthly installment vesting retroactively as of October 1, 2003.
Notwithstanding the foregoing, a portion of the shares subject to your outstanding stock options may vest on an accelerated basis pursuant to Section 6 below. Except as provided herein, such stock options will be subject to the provisions of
the equity incentive plan of the Company under which the options are granted and the applicable form of stock option agreement thereunder (the “Plan Documents”). 
 3. Other Activities During Employment. 
 3.1 Activities. Except with
the prior written consent of the Board, you will not during your employment undertake or engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and
not-for-profit activities so long as such activities do not materially interfere with the performance of your job duties. 

3.2 Investment and Interests. Except as permitted by Section 3.3 below, during your employment you agree not to acquire,
assume or participate in, directly or indirectly, any position, investment or interest known by you to be adverse or antagonistic to the Company, or its business or prospects, financial or otherwise. 

3.3 Noncompetition. During the term of your employment by the Company except on behalf of the Company, you will not directly or
indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any
other person, corporation, firm, partnership or other entity whatsoever that competes with the Company anywhere in the world, in any line of business engaged in (or planned to be engaged in) by the Company; provided, however, that anything
above to the contrary notwithstanding, you may own, as a passive investor, securities of any entity, so long as your direct holdings in any one such corporation do not in the aggregate constitute more than one percent (1%) of the voting stock
of such corporation. 
 4. Company Policies; Proprietary Information and Inventions Agreement. You
acknowledge your ongoing obligations under the Company’s Employee Agreement on Confidential Information and Inventions, a copy of which is attached hereto as Exhibit B. You further acknowledge your obligation to abide by the Company’s
rules, policies and procedures. 

 5. Termination of Employment. 

5.1 At-Will Employment Relationship. Your employment with the Company shall continue to be at-will. Either you or the Company may
terminate the employment relationship at any time, with or without Cause and with or without advance notice. 
 5.2
Termination for Cause. 
 (a) If the Company terminates your employment at any time for Cause (as defined below),
your salary shall cease on the date of termination and you shall not be entitled to severance pay, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required
in such event by applicable law or the terms of applicable benefit plans. The continued vesting of any stock options held by you shall cease on the termination date, and your right to exercise vested option shares shall be governed by the terms of
the Company’s applicable stock option plans and the corresponding stock option agreements. 
 (b) Definition of
Cause. For purposes of this agreement, “Cause” means the occurrence of any one or more of the following: (i) your conviction of, or plea of no contest with respect to, any felony involving fraud, dishonesty or moral turpitude;
(ii) your participation in a fraud or act of dishonesty that results in material harm to the Company; (iii) your intentional material violation of any contract or agreement between you and the Company, including but not limited to this
agreement or your Employee Agreement on Confidential Information and Inventions, or your violation of any statutory duty that you owe to the Company, but only if you do not correct such violation within thirty (30) days after written notice
thereof has been provided to you; or (iv) your gross negligence or willful neglect of your job duties, as determined by the Board in good faith, but only if you do not correct such violation within thirty (30) days after written notice
thereof has been provided to you. 
 5.3 Severance Benefits For Termination Without Cause or Resignation for Good Reason.

 (a) If the Company terminates your employment without Cause or you resign your employment for Good Reason (defined
below), you will be eligible to receive twelve (12) months of the greater of (i) your base salary in effect as of such termination date or (ii) your base salary as set forth in Section 2.1, subject to payroll deductions and
required withholdings and net of any amounts earned by you pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 3.1). In addition
you will be eligible to receive your potential annual discretionary bonus amount set forth in Section 2.2, determined as if all performance targets established by the Board have been satisfied, pro-rated for the number of months elapsed in the
year in which your employment terminates. This base salary and bonus severance will be paid according to the Company’s payroll procedures during the twelve (12) month period following the termination date. Moreover, if you timely elect
continued coverage of your group health 

 
insurance under COBRA, the Company will pay your premiums for COBRA coverage for up to twelve (12) months following the termination date, provided that such payments shall cease if you
obtain full-time employment within such period. Upon such termination, the vesting of all stock options held by you shall be accelerated such that the options are fully vested and exercisable upon the termination date and such stock options shall be
exercisable for the remainder of their original term, without regard to your termination of employment. Upon approval by the Board of this Agreement, your currently outstanding stock options shall be amended to the extent necessary to provide for
the foregoing accelerated vesting and extended exercisability. Your receipt of any severance benefits under this Section 5.3 is contingent upon your signing and making effective the Release Agreement (attached as Exhibit A) on or after the
termination date. 
 (b) Definition of Good Reason. For purposes of this Agreement, “Good Reason” shall mean
any one of the following events that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee of the Company (but not merely a change in reporting relationships); (ii) a
reduction in your level of compensation (including base salary, fringe benefits and target bonuses under any corporate-performance based bonus or incentive programs); (iii) a relocation of your place of employment by more than twenty
(20) miles; or (iv) the Company’s material breach of this Agreement. Notwithstanding the foregoing, you must provide the Company with thirty (30) days’ advance written notice of Company’s conduct giving rise to Good
Reason (the “Cure Period”) and during the Cure Period, the Company may attempt to rescind or correct the matter giving rise to Good Reason. If the Company does not rescind or correct the conduct giving rise to Good Reason to your
reasonable satisfaction by the expiration of the Cure Period, your employment will then terminate with Good Reason. 
 6.
Change in Control. 
 6.1 Definitions. 
 (a) “Change in Control” shall mean an Ownership Change Event or a series of related Ownership Change Events (collectively, a “Transaction”) wherein the stockholders of the
Company immediately before the Transaction do not retain direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding securities of the Company or, in the case of a Transaction
described in Section 6.1(b)(iii) below, the corporation or other business entity to which the assets of the Company were transferred (the “Transferee”), as the case may be. For purposes of the preceding sentence, indirect beneficial
ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities that own the Company or the Transferee, as the case may be, either directly or through
one or more subsidiary corporations or other business entities. 
 (b) “An “Ownership Change
Event” shall be deemed to have occurred if any of the following occurs with respect to the Company: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more
than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation in which the Company is a party; or (iii) the sale, exchange or transfer of all or substantially all of the assets of the Company. 

 6.2 Stock Options. At the closing of a Change in Control, your
outstanding stock options shall become vested and exercisable with respect to fifty percent (50%) of your then-unvested shares of the Company’s common stock subject thereto. In addition, in the event that within twelve (12) months
following a Change in Control, the Company terminates your employment without Cause (as defined above) or you resign for Good Reason (as defined above) (a “Change in Control Termination”), any remaining unvested portion of all stock
options held by you shall have the vesting accelerated such that all options are fully vested and exercisable as of the date of the Change in Control Termination (the “Acceleration”). As a precondition of receiving the Acceleration, you
must first sign and allow to become effective a general release of claims in favor of the Company in a form acceptable to the Company. 
 6.3 Parachute Payments After the Listing Date. 
 (a) After the
Listing Date (as defined below), if any payment or distribution in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or for your benefit, whether under this Agreement or otherwise (a “Payment”),
would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) (together with any interest or penalties imposed with respect to such excise tax, the “Excise Tax”),
then you will be entitled to receive from the Company an additional payment (the “Gross-Up Payment”) in an amount equal to (i) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the Payment
(the “First Reimbursement Payment”), (ii) all federal, state and local income taxes and employment taxes on the First Reimbursement Payment, and (iii) all Excise Taxes (including any interest or penalties imposed with respect to
such taxes) on the First Reimbursement Payment. For purposes of this provision, the term “Listing Date” means the date of the sale of the Company’s securities to the general public pursuant to an initial public offering under a
Registration Statement filed with and declared effective by the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended. 
 (b) All determinations required to be made under this Section 6.3 including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be
utilized in arriving at such determination, shall be made by the nationally recognized certified public accounting firm used by the Company immediately prior to the effective date of the Change in Control or, if such firm declines to serve, such
other nationally recognized certified public accounting firm as you may designate (the “Accounting Firm”). Any determination by the Accounting Firm shall be binding upon the Company and you. The Accounting Firm may make reasonable
assumptions and approximations concerning applicable taxes and may rely on reasonable, good-faith interpretations concerning the application of Sections 280G and 4999 of the Code. 

 7. General Provisions. 

7.1 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect
any other provision or any other jurisdiction, but such invalid, illegal or unenforceable provision will be reformed, construed and enforced in such jurisdiction so as to render it valid, legal, and enforceable consistent with the intent of the
parties insofar as possible. 
 7.2 Entire Agreement. This Agreement, together with its exhibits, constitutes the
entire and exclusive agreement between you and the Company, and it supersedes any prior agreement, promise, representation, or statement, written or otherwise, between you and the Company with regard to this subject matter, including the letter
dated December 12, 2002. It is entered into without reliance on any promise, representation, statement or agreement other than those expressly contained or incorporated herein, and it cannot be modified or amended except in a writing signed by
you and a duly authorized officer of the Company. 
 7.3 Successors and Assigns. This Agreement is intended to
bind and inure to the benefit of and be enforceable by you, the Company and your and its respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties hereunder and you may not assign any of
your rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. 
 7.4
Governing Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of California as applied to contracts made and to be performed entirely within California.

 7.5 Attorneys’ Fees. If either party hereto brings any action to enforce his or its rights hereunder, the
prevailing party in such action shall be entitled to be paid by the other party such prevailing party’s reasonable attorneys fees and costs incurred in such action. In addition, the Company shall reimburse you for your attorneys fees and costs
(not to exceed $2,500 in the aggregate) reasonably incurred by you in connection with this Agreement. 

 To indicate your acceptance of the Company’s offer of continued employment, please sign and date this
Agreement in the space provided below and return it to me. 
 Sincerely, 

 

			
	Metabolex, Inc.
		
	By:	 	

		 	 A. Barr Dolan

Chairman of the Compensation Committee of the Board

  

							
	Accepted and agreed:	 		 	
				
	

	 		 		 	March 4, 2004
	HAROLD VAN WART	 		 		 	DATE

 EXHIBIT A – Release Agreement 
 EXHIBIT B – Employee Agreement on Confidential Information and Inventions 

 EXHIBIT A 

RELEASE AGREEMENT 
 (To be signed on or after the Separation Date) 
 I understand that my employment with
Metabolex, Inc. (the “Company”) terminated effective                     ,
                     (the “Separation Date”). The Company has agreed that if I choose to sign this Release Agreement
(“Release”), the Company will provide certain severance benefits (minus the required withholdings and deductions) pursuant to the terms of the employment agreement dated March 1, 2004 (the “Agreement”). I understand that I
am not entitled to such severance benefits unless I sign this Release, and it becomes fully effective. I understand that, regardless of whether I sign this Release, the Company will pay me all of my accrued salary and vacation through the Separation
Date, to which I am entitled by law. 
 In consideration for the severance benefits I am receiving under the Agreement, as described therein, I
hereby agree to release the Company and its officers, directors, agents, attorneys, employees, shareholders, parents, subsidiaries, affiliates, successors, and assigns, of and from any and all claims, liabilities, demands, causes of action, costs,
expenses, attorneys’ fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known or unknown, suspected and unsuspected, disclosed and undisclosed, liquidated or contingent, arising out of or in any
way related to agreements, events, acts or conduct at any time prior to and including the execution date of this Release, including but not limited to: any and all such claims and demands directly or indirectly arising out of or in any way connected
with my employment with the Company or the termination of that employment; claims or demands related to salary, bonuses, commissions, incentive payments, stock, stock options, or any ownership or equity interests in the Company, vacation pay,
personal time off, fringe benefits, expense reimbursements, severance benefits, or any other form of compensation; claims pursuant to any federal, any state or any local law, statute, common law or cause of action including, but not limited to, the
federal Civil Rights Act of 1964, as amended; the federal Americans with Disabilities Act of 1990; the federal Employee Retirement Income Security Act; the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”); the
California Fair Employment and Housing Act, as amended; tort law; contract law; wrongful discharge; discrimination; harassment; fraud; misrepresentation; defamation; libel; emotional distress; and breach of the implied covenant of good faith and
fair dealing. 
 In releasing claims unknown to me at present, I am waiving all rights and benefits under Section 1542 of the
California Civil Code, and any law or legal principle of similar effect in any jurisdiction: “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release,
which if known by him must have materially affected his settlement with the debtor.” 
 I acknowledge that I am knowingly and
voluntarily waiving and releasing any rights I may have under the ADEA and that the consideration given for the waiver in the above paragraphs is in addition to anything of value to which I was already entitled. I have been advised by this writing,
as required by the ADEA, that: (a) my waiver and release do not apply to any claims that may arise after my signing of this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have twenty-one
(21) days within which to consider this Release 

 (although I may choose to voluntarily sign this Release earlier); (d) I have seven (7) days after
I sign this Release to revoke it; and (e) this Release will not be effective until the eighth day after this Release has been signed by me. 
 I accept and agree to the terms and conditions stated above: 

					
			
	 	 		 	 
	Date	 		 	Harold Van Wart

 EXHIBIT B 

EMPLOYEE AGREEMENT ON CONFIDENTIAL 
 INFORMATION AND INVENTIONS 

  
 

 
 October 10, 2007 
 Harold Van Wart 
 c/o Metabolex, Inc. 
 3876 Bay Center Place 
 Hayward, CA 94545 
 Dear Hal: 
 This letter agreement (the “Amendment”) amends the terms of your employment
agreement dated March 1, 2004 (the “Original Agreement”) with Metabolex, Inc. (the “Company”) in order to address the requirements of Section 409A of the Internal Revenue Code, as amended (the “Code”). The
Original Agreement is hereby amended only as expressly set forth herein. All other terms and conditions of the Original Agreement continue in full force and effect. 
 Section 5.3 is amended and restated as follows: 
 5.3 Severance
Benefits For Termination Without Cause or Resignation for Good Reason. 
 (a) If the Company terminates your
employment without Cause and other than as a result of your death or disability, or if you resign your employment for Good Reason (defined below), you will be eligible to receive the severance benefits described in this Section 5.3. You will be
eligible to receive, subject to payroll deductions and required withholdings and net of any amounts earned by you pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described
in the last sentence of Section 3.1), continuation for twelve (12) months of the greater of (i) your base salary in effect as of such termination date or (ii) your base salary as set forth in Section 2.1. In addition you
will be eligible to receive your potential annual discretionary bonus amount set forth in Section 2.2, determined as if all performance targets established by the Board have been satisfied, pro-rated for the number of months elapsed in the year
in which your employment terminates. You agree to notify the Company promptly of any amount earned by you from other employment or a consulting engagement while you are receiving severance payments under this Agreement. Moreover, if you timely elect
and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay your premiums for COBRA coverage for up to twelve (12) months following the termination date, provided that such payments shall cease if
you obtain full-time employment, or cease to be eligible for COBRA, within such period. You agree to notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this Agreement. Upon such
termination, the vesting of all compensatory equity awards held by you shall be accelerated such that the awards are fully vested and exercisable upon the termination date and all stock options shall be exercisable for the remainder of their
original term, without regard to your termination of employment. Upon approval by the Board of this Agreement, any currently outstanding compensatory equity awards shall be amended to the extent necessary to provide for the foregoing accelerated
vesting. Your receipt of any severance benefits under this Section 5.3 is contingent upon your signing and making effective within forty-five (45) days after the 

 
  
 Metabolex, Inc.    3876 Bay Center Place, Hayward, CA 94545    Phone: (510) 293-8800    www.metabolex.com 

 Harold Van Wart 
 Page 2 
  

 termination date, a full, general release of all claims against the Company in a form acceptable to the
Company containing the language set forth in the Release Agreement attached as Exhibit A on or after the termination date. This base salary and bonus severance will be paid in substantially equal installments over the twelve (12) month period
following the termination date according to the Company’s payroll procedures; provided, however, that no payments will be made to you prior to the effective date of the Release Agreement. On the first payroll pay day following the effective
date of the Release Agreement, the Company will pay you the cash severance amounts you would have received on or prior to such date in a lump sum, with the balance of the cash payments being made as originally scheduled. 

(b) Definition of Good Reason. For purposes of this Agreement, “Good Reason” shall mean any one of the following events
that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee of the Company (but not merely a change in reporting relationships); (ii) a material reduction in your level of
compensation (including base salary, fringe benefits and target bonuses under any corporate-performance based bonus or incentive programs); (iii) a relocation of your place of employment that results in an increase to your round trip commute of
more than twenty (20) miles; or (iv) the Company’s material breach of this Agreement. Notwithstanding the foregoing, you must provide written notice to the General Counsel of the Company within thirty (30) days after the date on
which such event first occurs, and allow the Company thirty (30) days thereafter (the “Cure Period”) during which the Company may attempt to rescind or correct the matter giving rise to Good Reason. If the Company does not rescind or
correct the conduct giving rise to Good Reason to your reasonable satisfaction by the expiration of the Cure Period, your employment will then terminate with Good Reason as of such thirtieth day. 

The following is added as Section 5.4: 
 5.4 Application of Section 409A. If the Company (or, if applicable, the successor entity thereto) determines that the severance payments and benefits provided for in this Agreement (the
“Agreement Payments”) constitute “deferred compensation” under Section 409A of the Internal Revenue Code (together, with any state law of similar effect, “Section 409A”) and you are a “specified employee”
of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) (a “Specified Employee”), then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under
Section 409A, the timing of the Agreement Payments shall be delayed as follows: on the earliest to occur of (i) the date that is six months and one day after the termination date or (ii) the date of your death (such earliest date, the
“Delayed Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum of the Agreement Payments that you would otherwise have received through the Delayed
Initial Payment Date if the commencement of the payment of the Agreement Payments had not been delayed pursuant to this Section 6.5 and (B) commence paying the balance of the Agreement Payments in accordance with the applicable payment
schedules set forth in this Agreement. For the avoidance of doubt, it is intended that (1) each installment of the Agreement Payments provided in this Agreement is a separate “payment” for purposes of Section 409A, (2) all
Agreement Payments satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under of Treasury Regulation 1.409A-1(b)(4) and 1.409A-l(b)(9)(iii), and (3) the Agreement Payments consisting of
COBRA premiums also satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation 1.409A-l(b)(9)(v). 

  
  

www.metabolex.com 

 Harold Van Wart 
 Page 3 
  

 Section 6.2 is amended and restated as follows: 

6.2 Stock Awards. At the closing of a Change in Control, your outstanding compensatory equity awards shall become vested and
exercisable with respect to fifty percent (50%) of your then-unvested shares of the Company’s common stock subject thereto. In addition, in the event that within twelve (12) months following a Change in Control, the Company terminates
your employment without Cause (as defined above) and other than as a result of your death or disability, or you resign for Good Reason (as defined above) (a “Change in Control Termination”), any remaining unvested portion of all
compensatory equity awards held by you shall have the vesting accelerated such that all awards are fully vested and exercisable as of the date of the Change in Control Termination (the “Acceleration”). As a precondition of receiving the
Acceleration, you must first sign and make effective on or after the termination date a full, general release of claims in favor of the Company within forty-five (45) days after the termination date in a form acceptable to the Company
containing the language set forth in the Release Agreement attached hereto as Exhibit A. 
 Section 6.3 is amended and restated as
follows: 
 6.3 Parachute Payments After the Listing Date. 

(a) After the Listing Date (as defined below), if any payment or distribution in the nature of compensation (within the meaning
of Section 280G(b)(2) of the Code) to you or for your benefit, whether under this Agreement or otherwise (a “Payment”), would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended
(the “Code”) (together with any interest or penalties imposed with respect to such excise tax, the “Excise Tax”), then you will be entitled to receive from the Company an additional payment (the “Gross-Up Payment”) in
an amount equal to (i) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the Payment (the “First Reimbursement Payment”), (ii) all federal, state and local income taxes and employment
taxes on the First Reimbursement Payment, and (iii) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the First Reimbursement Payment. For purposes of this provision, the term “Listing Date”
means the date of the sale of the Company’s securities to the general public pursuant to an initial public offering under a Registration Statement filed with and declared effective by the U.S. Securities and Exchange Commission under the
Securities Act of 1933, as amended. 
 (b) All determinations required to be made under this Section 7.3 including
whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by the nationally recognized certified public tax accounting firm used by the
Company or, if such firm declines to serve, such other nationally recognized certified public tax accounting firm as you may designate (the “Accounting Firm”). The Accounting Firm may make reasonable assumptions and approximations
concerning applicable taxes and may rely on reasonable, good-faith interpretations concerning the application of Sections 280G and 4999 of the Code. The 

  
  

www.metabolex.com 

 Harold Van Wart 
 Page 4 
  

 
Accounting Firm shall provide its calculations, together with detailed supporting documentation, to the Company and you within thirty (30) calendar days after the date on which your right to
a Payment is triggered (if requested at that time by the Company or you) and/or at such other times as requested by the Company or you. If the Accounting Firm determines that no Excise Tax is payable with respect to a Payment, it shall furnish the
Company and you with an opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment. If the Accounting Firm determines that an Excise Tax is payable with respect to a Payment, it shall furnish to the Company
and you an opinion reasonably acceptable to you of the amount of Excise Tax payable with respect to the Payments and the amount of Gross-Up Payment due to you. The Company will pay the Gross-Up Payment to you within thirty (30) days of the date
the Company receives the Accounting Firm’s opinion, but in no event later than the end of your tax year following your tax year in which you pay the Excise Tax. The Company shall bear all reasonable expenses with respect to the determinations
by the Accounting Firm required to be made hereunder. Any determination by the Accounting Firm shall be binding upon the Company and you. 
 To
indicate your agreement to this Amendment, please sign and date this Amendment in the space provided below and return it to me. 
 Sincerely,

 Metabolex, Inc. 

			
		
	By:	 	

		 	 Ed Penhoet
 Chairman
of the Board

  

							
	Accepted and agreed:	 		 	
				
	

;	 		 		 	October 15, 2007
	HAROLD VAN WART	 		 		 	DATE

  
  

www.metabolex.com 

 EXHIBIT B 

RELEASE AGREEMENT 
 (To be signed on or after the Separation Date) 
 I understand that my
employment with Metabolex, Inc. (the “Company”) terminated effective                     ,
                     (the “Separation Date”). The Company has agreed that if I choose to sign this Release Agreement
(“Release”), the Company will provide certain severance benefits (minus the required withholdings and deductions) pursuant to the terms of the employment agreement dated
                     (as amended, the “Agreement”). I understand that I am not entitled to such severance benefits unless I sign
this Release, and it becomes fully effective. 
 I understand that this Release, together with the Agreement, constitutes the
complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated therein. 

I hereby confirm my obligations under my Employee Agreement on Confidential Information and Inventions with the Company. 

I hereby represent that I have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits
and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already filed a claim. 

In exchange for the consideration provided to me by this Release that I am not otherwise entitled to receive, I hereby generally and
completely release Company and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and all claims,
liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to: (a) all
claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay,
expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and
fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination,
harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as
amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). Nothing in this Release shall prevent me from challenging this Release by filing, cooperating with, or participating in any
proceeding before the 

  
  

www.metabolex.com 

 
Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover
any monetary benefits in connection with any challenge to my Release. 
 I acknowledge that I am knowingly and voluntarily
waiving and releasing any rights I may have under the ADEA (“ADEA Waiver”). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already
entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an
attorney prior to signing this Release; (c) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke
the ADEA Waiver; and (e) the ADEA Waiver will not be effective until the date upon which the revocation period has expired unexercised, which will be the eighth day after I sign this Release. 

I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A
general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the
debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 

I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than
twenty-one (21) days following the date it is provided to me. 
 I accept and agree to the terms and conditions stated above:

					
			
	 	 		 	  

	Date	 		 	Harold Van Wart

  
  

www.metabolex.comEX-10.21

 Exhibit 10.21 

 
 

 
 June 5, 2007 
 Charles A. McWherter 
 1320 Christmas Valley Drive 

Chesterfield, MO 63005 
 Dear Chuck: 

Metabolex, Inc. (the “Company”) is pleased to offer you employment as Senior Vice President, Research and Preclinical Development on the
following terms: 
 1. Position, Duties and Responsibilities. Subject to the terms set forth herein, the Company agrees to
employ you in the position of Senior Vice President, Research and Preclinical Development and you hereby accept such employment effective as of a mutually acceptable start date. As Senior Vice President, Research and Preclinical Development, you
will report to the Company’s Chief Executive Officer (“CEO”), and will perform the duties customarily associated with this position and such other duties as are assigned to you by the CEO. You shall devote your full business time and
attention to the business affairs of the Company, except for reasonable vacations and periods of illness or incapacity permitted by the Company’s general employment policies. The employment relationship between you and the Company shall also be
governed by the general employment policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the terms of this letter agreement differ from or are in
conflict with the Company’s general employment policies or practices, this letter agreement shall control. 
 2.
Compensation and Employee Benefits. 
 2.1 Base Salary. Your base salary will be two hundred ninety thousand dollars
($290,000) on an annualized basis, less payroll deductions and required withholdings, paid according to the Company’s regular payroll schedule and procedures. Your base salary may be modified by the Company in its sole discretion. For your
initial year of employment, any merit increase you receive will not be pro rated for the time period for which you were employed by the Company during the year. 
 2.2 Hiring Bonus. On the first regular pay date after the date upon which you commence your employment (your “Employment Commencement Date”) the Company will pay to you a hiring bonus
(the “Hiring Bonus”) in the amount of fifty thousand dollars ($50,000), less payroll deductions and required withholdings. The Hiring Bonus shall be repaid to the Company, in full, if within one (1) year of your Employment
Commencement Date your employment with the Company (and its successors) is terminated either (i) by you or (ii) by the Company for Cause (as defined in Section 7.2(b)). 

 
  
 Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510) 293-8800     www.metabolex.com 

 

 
  
 2.3 Relocation Bonus.
On the first regular pay date after your Employment Commencement Date the Company will pay to you a relocation bonus (the “Relocation Bonus”) in the amount of forty thousand five hundred dollars ($40,500), less payroll deductions and
required withholdings. The Relocation Bonus shall be repaid to the Company, in full, if within one (1) year of your Employment Commencement Date your employment with the Company (and its successors) is terminated either (i) by you or
(ii) by the Company for Cause (as defined in Section 7.2(b)). Attached as Exhibit A is a copy of the Company’s relocation expense policy. 
 2.4 Discretionary Bonus. You will be eligible to participate in the Company’s annual bonus program in recognition of your performance and achievement of agreed upon goals. Your target annual
bonus will be equal to twenty-five percent (25%) of your annual base salary. Your actual bonus, if any, will be determined by the Company’s Board of Directors (“Board”), or a subcommittee thereof, in its sole discretion, based
upon its evaluation of your performance, the Company’s performance, and any other considerations it deems relevant. For your initial year of employment, your bonus will be pro rated for the number of months elapsed in the bonus period
for which you were employed by the Company. You must be employed through the bonus payment date in order to be eligible for any such bonus. Any bonus payment shall be subject to payroll deductions and required withholdings. 

2.5 Employee Benefits. You shall be entitled to all employee benefits, including vacation accrual of twenty (20) days per
year and health and disability benefits, for which you are eligible under the terms and conditions of the standard Company benefit plans, which may be in effect from time to time and provided by the Company to its senior executive-level employees
generally. Currently, such benefits include eight paid holidays and four floating holidays per year, as well as paid sick leave of up to ten days per year. Notwithstanding the foregoing, the Company reserves the right to adopt, amend or discontinue
any employee benefit plan or policy, including changes required by applicable law. 
 2.6 Stock Options. Subject to the
approval of the Board you will be granted a stock option to purchase four hundred fifty thousand (450,000) shares of Company common stock, at a per share exercise price equal to the per share fair market value of the common stock on the date of
grant, as determined by the Board, pursuant to the Company’s equity incentive plan. Option grants are made at regular Board meetings held approximately once each calendar quarter. Your option grant will be considered at the first regular Board
meeting following your employment commencement date. The term of such stock option will be ten (10) years, subject to earlier expiration in the event of the termination of your service with the Company. Such stock option will be immediately
exercisable, if you elect to do so, but the purchased shares shall be subject to repurchase by the Company in the event that your service with the Company terminates before you become vested in the shares, at the lower of (1) the original
exercise price or (2) the then-fair market value of the Company’s common stock. You will be vested in, and the Company’s repurchase right, if applicable, shall not apply as to, twenty-five percent (25%) of the shares covered by
the option on the first year anniversary of your Employment 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	2

 

 
  
 
Commencement Date and the remaining seventy-five percent (75%) of the shares covered by the option will vest in thirty-six (36) equal monthly installments with the first monthly
installment vesting one month following the first year anniversary of your Employment Commencement Date, as long as you remain in continuous service with the Company. Notwithstanding the foregoing, a portion of the shares subject to your outstanding
stock options may vest on an accelerated basis pursuant to Sections 7 or 8. Except as provided herein, such stock options will be subject to the provisions of the equity incentive plan of the Company under which the options are granted and the
applicable form of stock option agreement thereunder (the “Plan Documents”). 
 3. Other Activities During
Employment. 
 3.1 Activities. Except with the prior written consent of the CEO, you will not, during your employment
with the Company, undertake or engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and not-for-profit activities so long as such activities do not interfere
with the performance of your job duties. 
 3.2 Investments and Interests. Except as permitted by the first sentence of
Section 3.1 and by Section 3.3, during your employment you agree not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by you to be adverse or antagonistic to the Company, or its
business or prospects, financial or otherwise. 
 3.3 Noncompetition. During the term of your employment by the Company,
except on behalf of the Company, you will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested
in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever that competes with the Company anywhere in the world, in any line of business engaged in (or planned to be engaged
in) by the Company; provided, however, that anything above to the contrary notwithstanding, you may own, as a passive investor, securities of any entity, so long as your direct holdings in any one such corporation do not in the aggregate
constitute more than one percent (1%) of the voting stock of such corporation. 
 4. Company Policies; Confidential
Information and Inventions Agreement. You acknowledge your obligations under the Company’s Employee Agreement on Confidential Information and Inventions, a copy of which is attached as Exhibit B. You further acknowledge your obligation to
abide by the Company’s rules, policies and procedures. 
 5. Immigration. The Immigration Reform and Control Act of
1986 requires that every person present proof to the Company of their identity and eligibility and/or authorization to accept employment with the Company. In order to comply with this law, and before you can

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	3

 

 
  
 
become a Company employee, you must provide appropriate documentation to prove both your identity and legal eligibility to be employed at the Company. Please be sure to bring this
documentation with you to your employee orientation. If you are working in this country on a VISA, you will need to provide copies of this documentation at your employee orientation. Failure to do so may result in over withholding of taxes.

 6. Your Representations and Warranties. 
 6.1 No Breach of Contract. You represent and warrant that the execution and delivery of this letter agreement by you and the performance of your obligations hereunder will not conflict with or
breach any agreement, order or decree to which you are a party or by which you are bound. You warrant that you are subject to no employment agreement or restrictive covenant preventing full performance of your duties under this letter agreement.

 6.2 No Conflict of Interest. You warrant that you are not, to the best of your knowledge and belief, involved in any
situation that might create, or appear to create, a conflict of interest with your loyalty to or duties for the Company. 

6.3 Notification of Materials or Documents from Other Employers. You further warrant that you have not brought and will not bring
to the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former
employer for their possession and use. 
 6.4 Notification of Other Post-Employment Obligations. You also understand
that, as part of your employment with the Company, you are not to breach any obligation of confidentiality that you have to former employers, and you agree to honor all such obligations to former employers during your employment with the Company.

 7. Termination of Employment. 
 7.1 At-Will Employment Relationship. Your employment with the Company shall be at-will. Either you or the Company may terminate the employment relationship at any time, with or without Cause and
with or without advance notice. 
 7.2 Termination for Cause. 

(a) If the Company terminates your employment at any time for Cause (as defined below), your salary shall cease on the date of
termination and you shall not be entitled to severance pay, COBRA premium payments, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required in such event by
applicable law or the terms of applicable benefit plans. The continued vesting of any stock options held by you shall cease on your employment termination date, and your right to exercise vested option shares shall be governed by the Plan Documents.

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	4

 

 
  
 (b) Definition of
Cause. For purposes of this agreement, “Cause” means the occurrence of any one or more of the following: (i) your conviction of, or plea of no contest with respect to, any felony or any crime involving fraud, dishonesty or moral
turpitude; (ii) your participation in a fraud or act of dishonesty that results in material harm to the Company; (iii) your intentional material violation of any contract or agreement between you and the Company, including but not limited
to this letter agreement or your Employee Agreement on Confidential Information and Inventions, or your violation of any statutory duty that you owe to the Company, but only if you do not correct such violation within thirty (30) days after
written notice thereof has been provided to you; or (iv) your gross negligence or willful neglect of your job duties, as determined by the Board in good faith, but only if you do not correct such violation within thirty (30) days after
written notice thereof has been provided to you. 
 7.3 Severance Benefits For Termination Without Cause or Resignation for
Good Reason. 
 (a) If the Company terminates your employment without Cause or you resign your employment for Good
Reason (defined below), you will be eligible to receive the severance benefits described in this Section 7.3. You will be eligible to receive, subject to payroll deductions and required withholdings and net of any amounts earned by you pursuant
to any employment or consulting arrangements obtained by you following such termination (other than the activities described in Section 3.1), continuation for twelve (12) months of the greater of (i) your base salary in effect as of
such termination date or (ii) your base salary as set forth in Section 2.1. In addition you will be eligible to receive your potential annual discretionary bonus amount set forth in Section 2.4, determined as if all performance
targets established by the Board have been satisfied, pro-rated for the number of months elapsed in the year in which your employment terminates. This base salary and bonus severance will be paid according to the Company’s payroll procedures
during the twelve (12) month period following the termination date. You agree to notify the Company promptly of any amount earned by you from other employment or a consulting engagement while you are receiving severance payments under this
letter agreement. Moreover, if you timely elect and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay your premiums for COBRA coverage for up to twelve (12) months following the termination
date, provided that such payments shall cease if you obtain full-time employment within such period. You agree to notify the Company promptly if you become eligible for health care benefits while the Company is paying your COBRA premiums under this
letter agreement. Upon termination without Cause or for Good Reason, the vesting of all stock options held by you shall be accelerated such that the options are fully vested and exercisable as of the termination date. Your receipt of any severance
benefits under this Section 7.3 is contingent upon your signing and making effective a full, general release of all claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement
attached as Exhibit C on or after the termination date. 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	5

 

 
  
 (b) Definition of Good
Reason. For purposes of this letter agreement, “Good Reason” shall mean any one of the following events that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee
of the Company (but not merely a change in reporting relationships); (ii) a reduction in your level of compensation (including base salary and target bonuses under any corporate-performance based bonus or incentive programs), or in fringe
benefits, other than changes applicable to all employees of the Company; (iii) a relocation of your place of employment by more than twenty (20) miles; or (iv) the Company’s material breach of this letter agreement.
Notwithstanding the foregoing, within thirty (30) days after the occurrence of an event or conduct giving rise to Good Reason, you must provide the Company with thirty (30) days’ advance written notice of termination, detailing the
Company’s conduct giving rise to Good Reason (the “Cure Period”) and during the Cure Period, the Company may attempt to rescind or correct the matter giving rise to Good Reason. If the Company does not rescind or correct the conduct
giving rise to Good Reason to your reasonable satisfaction by the expiration of the Cure Period, your employment will then terminate with Good Reason. 
 7.4 Voluntary or Mutual Termination. 
 (a) You may voluntarily
terminate your employment with the Company at any time without Good Reason. If you terminate without Good Reason, your salary shall cease on the date of termination and you shall not be entitled to severance pay, COBRA premium payments, pay in lieu
of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required in such event by applicable law or the terms of applicable benefit plans. The continued vesting of any stock
options held by you shall cease on the termination date, and your right to exercise vested option shares shall be governed by the Plan Documents. 
 (b) If at any time during the course of this letter agreement the parties by mutual consent decide to terminate this letter agreement, you and the Company shall do so by separate agreement setting
forth the terms and conditions of such termination. 
 7.5 Application of Section 409A. In the event that any
benefit provided herein shall fail to satisfy the distribution requirement of Section 409A(a)(2)(A) of the United States Internal Revenue Code (the “Code”) as a result of the application of Section 409A(a)(2)(B)(i) of the Code,
the payment of such benefit shall be delayed to the minimum extent necessary so that such benefits are not subject to the provisions of Section 409A(a)(l) of the Code. The Board may attach conditions to or adjust the amounts paid pursuant to
this Section 7.5 to preserve, as closely as possible, the economic consequences that would have applied in the absence of this Section 7.5; provided, however, that no such condition or adjustment shall result in the payments being
subject to Section 409A(a)(l) of the Code. 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	6

 

 
  
 8. Change in
Control. 
 8.1 Definitions. 
 (a) “Change in Control” shall mean an Ownership Change Event (as defined below) or a series of related Ownership Change Events (collectively, a “Transaction”) wherein the
stockholders of the Company immediately before the Transaction do not retain direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding securities of the Company or, in the
case of a Transaction described in Section 8.1(b)(iii), the corporation or other business entity to which the assets of the Company were transferred (the “Transferee”), as the case may be. For purposes of the preceding sentence,
indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities that own the Company or the Transferee, as the case may be, either
directly or through one or more subsidiary corporations or other business entities. 
 (b) An “Ownership Change
Event” shall be deemed to have occurred if any of the following occurs with respect to the Company: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than
fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation in which the Company is a party; or (iii) the sale, exchange or transfer of all or substantially all of the assets of the Company. 

8.2 Stock Options. At the closing of a Change in Control, your outstanding stock options shall become vested and
exercisable with respect to fifty percent (50%) of your then-unvested shares of the Company’s common stock subject thereto. In addition, in the event that within twelve (12) months following a Change in Control, the Company terminates
your employment without Cause or you resign for Good Reason (a “Change in Control Termination”), any remaining unvested portion of all stock options held by you shall have the vesting accelerated such that all options are fully vested and
exercisable as of the date of the Change in Control Termination (the “Acceleration”). As a precondition of receiving the Acceleration, you must first sign and make effective on or after the termination date a full, general release of
claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit C. 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	7

 

 
  
 8.3 Parachute Payments
After the Listing Date. 
 (a) After the Listing Date (as defined below), if any payment or distribution in the
nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or for your benefit, whether under this letter agreement or otherwise (a “Payment”), would be subject to the excise tax imposed by Section 4999 of
the Internal Revenue Code of 1986, as amended (the “Code”) (together with any interest or penalties imposed with respect to such excise tax, the “Excise Tax”), then you will be entitled to receive from the Company an additional
payment (the “Gross-Up Payment”) in an amount equal to (i) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the Payment (the “First Reimbursement Payment”); (ii) all federal,
state and local income taxes and employment taxes on the First Reimbursement Payment; and (iii) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the First Reimbursement Payment. For purposes of this
provision, the term “Listing Date” means the date of the sale of the Company’s securities to the general public pursuant to an initial public offering under a Registration Statement filed with and declared effective by the U.S.
Securities and Exchange Commission under the Securities Act of 1933, as amended. 
 (b) All determinations required to
be made under this Section 8.3 including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by the nationally recognized
certified public accounting firm used by the Company immediately prior to the effective date of the Change in Control or, if such firm declines to serve, such other nationally recognized certified public accounting firm as you may designate (the
“Accounting Firm”). Any determination by the Accounting Firm shall be binding upon the Company and you. The Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable,
good-faith interpretations concerning the application of Sections 280G and 4999 of the Code. 
 9. General Provisions.

 9.1 Severability. Whenever possible, each provision of this letter agreement will be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this letter agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability will not affect any other provision or any other jurisdiction, but such invalid, illegal or unenforceable provision will be reformed, construed and enforced in such jurisdiction so as to render it valid, legal, and enforceable
consistent with the intent of the parties insofar as possible. 
 9.2 Notices. Any notices provided hereunder must be in
writing and shall be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight courier, to the Company at its primary office location and to you at your address as listed
on the Company payroll. 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	8

 

 
  
 9.3 Waiver. If
either party should waive any breach of any provisions of this letter agreement, you or the Company shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this letter agreement.

 9.4 Entire Agreement. This letter agreement, together with its exhibits, constitutes the entire and exclusive
agreement between you and the Company, and it supersedes any prior agreement, promise, representation, or statement, written or otherwise, between you and the Company with regard to this subject matter. It is entered into without reliance on any
promise, representation, statement or agreement other than those expressly contained or incorporated herein, and it cannot be modified or amended except in a writing signed by you and a duly authorized officer of the Company. 

9.5 Counterparts. This letter agreement may be executed in separate counterparts, any one of which need not contain signatures of
more than one party, but all of which taken together will constitute one and the same letter agreement. 
 9.6 Headings.
The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 9.7 Successors and Assigns. This letter agreement is intended to bind and inure to the benefit of and be enforceable by you, the Company and your and its respective successors, assigns, heirs,
executors and administrators, except that you may not assign any of your duties hereunder and you may not assign any of your rights hereunder without the written consent of the Company. 

9.8 Governing Law. All questions concerning the construction, validity and interpretation of this letter agreement will be
governed by the law of the State of California as applied to contracts made and to be performed entirely within California. 

9.9 Attorneys’ Fees. If either party hereto brings any action to enforce your or its rights hereunder, the prevailing party
in such action shall be entitled to be paid by the other party such prevailing party’s reasonable attorneys’ fees and costs incurred in such action. 
 Enclosed is your Employee Agreement on Confidential Information and Inventions, which you should read carefully. 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	9

 

 
  
 To indicate your acceptance of the
Company’s offer, please sign this letter agreement in the space provided below and return it to me along with the signed Employee Agreement on Confidential Information and Inventions, in the stamped self-addressed envelope, which is enclosed.
This offer shall expire on June 15, 2007 if not accepted prior to such date. If you have any questions regarding this letter agreement, feel free to contact me. 
  

			
	Sincerely,
	
	METABOLEX, INC.
		
	By:	 	 
		 	Diana M. Petty
		 	VP of HR & Administration

  

					
	Accepted and agreed:	 		 	
			
	

	 		 	June 14, 2007
	Charles A. McWherter	 		 	

 EXHIBIT A – Relocation Expense Policy for New and Transferred Employees 

EXHIBIT B – Employee Agreement on Confidential Information and Inventions 

EXHIBIT C – Release Agreement 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	10

 

 
  
 October 10, 2007 

Charles A. McWherter 
 c/o Metabolex, Inc.

 3876 Bay Center Place 
 Hayward, CA
94545 
 Dear Chuck: 
 This letter
agreement (the “Amendment”) amends the terms of your employment agreement dated June 5, 2007 (the “Original Agreement”) with Metabolex, Inc. (the “Company”) in order to address the requirements of Section 409A
of the Internal Revenue Code, as amended (the “Code”). The Original Agreement is hereby amended only as expressly set forth herein. All other terms and conditions of the Original Agreement continue in full force and effect. 

Section 7.3 is amended and restated as follows: 
 7.3 Severance Benefits For Termination Without Cause or Resignation for Good Reason. 
 (a) If the Company terminates your employment without Cause and other than as a result of your death or disability, or if you resign your employment for Good Reason (defined below), you will be
eligible to receive the severance benefits described in this Section 7.3. You will be eligible to receive, subject to payroll deductions and required withholdings and net of any amounts earned by you pursuant to any employment or consulting
arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 3.1), continuation for twelve (12) months of the greater of (i) your base salary in effect as of such
termination date or (ii) your base salary as set forth in Section 2.1. In addition you will be eligible to receive your potential annual discretionary bonus amount set forth in Section 2.4, determined as if all performance targets
established by the Board have been satisfied, pro-rated for the number of months elapsed in the year in which your employment terminates. You agree to notify the Company promptly of any amount earned by you from other employment or a consulting
engagement while you are receiving severance payments under this letter agreement. Moreover, if you timely elect and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay your premiums for COBRA
coverage for up to twelve (12) months following the termination date, provided that such payments shall cease if you obtain full-time employment, or cease to be eligible for COBRA, within such period. You agree to notify the Company promptly if
you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. Upon such termination, the vesting of all compensatory equity awards held by you shall be accelerated such that the awards are fully vested
and exercisable upon the termination date. Upon approval by the Board of this letter agreement, any currently outstanding compensatory equity awards shall be amended to the extent necessary to provide for the foregoing accelerated vesting. Your
receipt of any severance benefits under this Section 7.3 is contingent upon your signing and making effective within forty-five (45) days after the termination date, a full, general release of all claims against the Company in a form
acceptable to the Company containing the 

  

	
	Metabolex, Inc.     3876 Bay Center Place, Hayward, CA 94545     Phone: (510)
293-8800     www.metabolex.com
	
	11

 Charles A. McWherter 
 Page 2 
  

 
language set forth in the Release Agreement attached as Exhibit C on or after the termination date. This base salary and bonus severance will be paid in substantially equal installments over the
twelve (12) month period following the termination date according to the Company’s payroll procedures; provided, however, that no payments will be made to you prior to the effective date of the Release Agreement. On the first payroll pay
day following the effective date of the Release Agreement, the Company will pay you the cash severance amounts you would have received on or prior to such date in a lump sum, with the balance of the cash payments being made as originally scheduled.

 (b) Definition of Good Reason. For purposes of this letter agreement, “Good Reason” shall mean any one of
the following events that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee of the Company (but not merely a change in reporting relationships); (ii) a material
reduction in your level of compensation (including base salary, fringe benefits and target bonuses under any corporate-performance based bonus or incentive programs); (iii) a relocation of your place of employment that results in an increase to
your round trip commute of more than twenty (20) miles; or (iv) the Company’s material breach of this letter agreement. Notwithstanding the foregoing, you must provide written notice to the General Counsel of the Company within thirty
(30) days after the date on which such event first occurs, and allow the Company thirty (30) days thereafter (the “Cure Period”) during which the Company may attempt to rescind or correct the matter giving rise to Good Reason. If
the Company does not rescind or correct the conduct giving rise to Good Reason to your reasonable satisfaction by the expiration of the Cure Period, your employment will then terminate with Good Reason as of such thirtieth day. 

Section 7.4 is amended and restated as follows: 
 7.4 Voluntary or Mutual Termination; Death; Disability. 
 (a) You
may voluntarily terminate your employment with the Company at any time without Good Reason. If you terminate without Good Reason or if your employment terminates as a result of your death or disability, your salary shall cease on the date of
termination and you shall not be entitled to severance, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required in such event by applicable law or the terms
of applicable benefit plans. The continued vesting of any compensatory equity awards held by you shall cease on the termination date, and your right to exercise vested awards (or be issued shares under such vested awards) shall be governed by the
terms of the Company’s applicable compensatory equity plans and the corresponding award agreements. 
 (b) If at
any time during the course of this letter agreement the parties by mutual consent decide to terminate this letter agreement, you and the Company shall do so by separate agreement setting forth the terms and conditions of such termination.

  
  

www.metabolex.com 

 Charles A. McWherter 
 Page 3 
  

 Section 7.5 is amended and restated as follows: 

7.5 Application of Section 409A. If the Company (or, if applicable, the successor entity thereto) determines that the
severance payments and benefits provided for in this letter agreement (the “Agreement Payments”) constitute “deferred compensation” under Section 409A of the Internal Revenue Code (together, with any state law of similar
effect, “Section 409A”) and you are a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) (a “Specified Employee”), then, solely to the extent
necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Agreement Payments shall be delayed as follows: on the earliest to occur of (i) the date that is six months and one day after
the termination date or (ii) the date of your death (such earliest date, the “Delayed Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum of
the Agreement Payments that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the Agreement Payments had not been delayed pursuant to this Section 7.5 and (B) commence paying
the balance of the Agreement Payments in accordance with the applicable payment schedules set forth in this letter agreement. For the avoidance of doubt, it is intended that (1) each installment of the Agreement Payments provided in this letter
agreement is a separate “payment” for purposes of Section 409A, (2) all Agreement Payments satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under of Treasury Regulation
1.409A-1(b)(4) and 1.409A-l(b)(9)(iii), and (3) the Agreement Payments consisting of COBRA premiums also satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation
1.409A-l(b)(9)(v). 
 Section 8.2 is amended and restated as follows: 

8.2 Stock Awards. At the closing of a Change in Control, your outstanding compensatory equity awards shall become vested and
exercisable with respect to fifty percent (50%) of your then-unvested shares of the Company’s common stock subject thereto. In addition, in the event that within twelve (12) months following a Change in Control, the Company terminates
your employment without Cause (as defined above) and other than as a result of your death or disability, or you resign for Good Reason (as defined above) (a “Change in Control Termination”), any remaining unvested portion of all
compensatory equity awards held by you shall have the vesting accelerated such that all awards are fully vested and exercisable as of the date of the Change in Control Termination (the “Acceleration”). As a precondition of receiving the
Acceleration, you must first sign and make effective on or after the termination date a full, general release of claims in favor of the Company within forty-five (45) days after the termination date in a form acceptable to the Company
containing the language set forth in the Release Agreement attached hereto as Exhibit C. 
 Section 8.3 is amended and restated as
follows: 
 8.3 Parachute Payments After the Listing Date. 

(a) After the Listing Date (as defined below), if any payment or distribution in the nature of compensation (within the meaning
of Section 280G(b)(2) of the Code) to you or for your benefit, whether under this letter agreement or otherwise (a “Payment”), would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as
amended (the “Code”) (together with any interest or penalties imposed with respect to such excise tax, the “Excise Tax”), then you will be entitled to receive from the Company an

  
  

www.metabolex.com 

 Charles A. McWherter 
 Page 4 
  

 
additional payment (the “Gross-Up Payment”) in an amount equal to (i) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the Payment (the
“First Reimbursement Payment”), (ii) all federal, state and local income taxes and employment taxes on the First Reimbursement Payment, and (iii) all Excise Taxes (including any interest or penalties imposed with respect to such
taxes) on the First Reimbursement Payment. For purposes of this provision, the term “Listing Date” means the date of the sale of the Company’s securities to the general public pursuant to an initial public offering under a
Registration Statement filed with and declared effective by the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended. 
 (b) All determinations required to be made under this Section 8.3 including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be
utilized in arriving at such determination, shall be made by the nationally recognized certified public tax accounting firm used by the Company or, if such firm declines to serve, such other nationally recognized certified public tax accounting firm
as you may designate (the “Accounting Firm”). The Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good-faith interpretations concerning the application of Sections
280G and 4999 of the Code. The Accounting Firm shall provide its calculations, together with detailed supporting documentation, to the Company and you within thirty (30) calendar days after the date on which your right to a Payment is triggered
(if requested at that time by the Company or you) and/or at such other times as requested by the Company or you. If the Accounting Firm determines that no Excise Tax is payable with respect to a Payment, it shall furnish the Company and you with an
opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment. If the Accounting Firm determines that an Excise Tax is payable with respect to a Payment, it shall furnish to the Company and you an opinion
reasonably acceptable to you of the amount of Excise Tax payable with respect to the Payments and the amount of Gross-Up Payment due to you. The Company will pay the Gross-Up Payment to you within thirty (30) days of the date the Company
receives the Accounting Firm’s opinion, but in no event later than the end of your tax year following your tax year in which you pay the Excise Tax. The Company shall bear all reasonable expenses with respect to the determinations by the
Accounting Firm required to be made hereunder. Any determination by the Accounting Firm shall be binding upon the Company and you. 

  
  

www.metabolex.com 

 Charles A. McWherter 
 Page 5 
  

 To indicate your agreement to this Amendment, please sign and date this Amendment in the space provided
below and return it to me. 
  

			
	Sincerely,
	
	Metabolex, Inc.
		
	By:	 	

		 	Harold Van Wart
		 	 Chief Executive Officer

  

					
	Accepted and agreed:	 		 	
			
	

	 		 	October 15, 2007
	CHARLES A. MCWHERTER	 		 	DATE

  
  

www.metabolex.com 

 EXHIBIT C 

RELEASE AGREEMENT 
 (To be signed on or after the Separation Date) 
 I understand that my
employment with Metabolex, Inc. (the “Company”) terminated effective
                            ,          (the
“Separation Date”). The Company has agreed that if I choose to sign this Release Agreement (“Release”), the Company will provide certain severance benefits (minus the required withholdings and deductions) pursuant to the terms of
the employment agreement dated                          (as amended, the “letter agreement”). I understand that
I am not entitled to such severance benefits unless I sign this Release, and it becomes fully effective. 
 I understand that
this Release, together with the letter agreement, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation
by the Company that is not expressly stated therein. 
 I hereby confirm my obligations under my Employee Agreement on
Confidential Information and Inventions with the Company. 
 I hereby represent that I have been paid all compensation owed and
for all hours worked, have received all the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already filed a
claim. 
 In exchange for the consideration provided to me by this Release that I am not otherwise entitled to receive, I hereby
generally and completely release Company and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and
all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to:
(a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for
discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of
1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). Nothing in this Release shall prevent me from challenging this Release by filing, cooperating with, or participating in any
proceeding before the 

  
  

www.metabolex.com 

 
Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover
any monetary benefits in connection with any challenge to my Release. 
 I acknowledge that I am knowingly and voluntarily
waiving and releasing any rights I may have under the ADEA (“ADEA Waiver”). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already entitled. I further
acknowledge that I have been advised by this writing, as required by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to
signing this Release; (c) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and
(e) the ADEA Waiver will not be effective until the date upon which the revocation period has expired unexercised, which will be the eighth day after I sign this Release. 
 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know
or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 
 I
acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than twenty-one (21) days following the date it is provided to me. 

I accept and agree to the terms and conditions stated above: 
  

					
	 	 		 	  

	Date	 		 	Charles A. McWherter

  
  

www.metabolex.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]